CCR8 is a chemokine receptor enriched on immunosuppressive ... Earlier this year, vopratelimab in combination with PD-1 inhibitor pimivalimab failed to outperform pimivalimab alone in the phase ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors. Other presentations highlight key ...

today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination ...